We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eisai and Biogen Idec Enter Collaboration
News

Eisai and Biogen Idec Enter Collaboration

Eisai and Biogen Idec Enter Collaboration
News

Eisai and Biogen Idec Enter Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eisai and Biogen Idec Enter Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eisai Co., Ltd. and Biogen Idec have announced that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.

The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idec's candidates for AD, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.

The collaboration initially will be centered on the co-development and co-commercialization of Eisai's two candidates: E2609, a β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-Aβ antibody.

These candidates have the potential to reduce Aβ plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression.

Eisai will serve as the operational and regulatory lead in the co-development of E2609 and BAN2401 and will pursue marketing authorizations for both compounds worldwide. In major markets, such as the United States and the European Union, Eisai and Biogen Idec will also co-promote the products following marketing approval.

Both companies will share overall costs, including research and development expenses, with Eisai booking all sales for E2609 and BAN2401 and with profits to be split between the companies.

Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments. The agreement also includes options for Eisai to receive an additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.

“This collaboration is a natural fit with our mission to develop therapies for patients with severe neurodegenerative diseases. Eisai's candidates have demonstrated compelling early data and complement our AD research while extending our pipeline in this critical area,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “Eisai is a pioneer in successfully developing and commercializing AD treatments. This history, combined with their strong scientific heritage, geographical reach and unwavering commitment to the AD community, makes Eisai an excellent collaboration partner to help drive our mission.”

Eisai Co., Ltd. President & CEO Haruo Naito added, “There exists an urgent need to develop AD therapies that suppress disease progression in order to effectively alleviate both the emotional burden of suffering and uncertainty experienced by patients and their families, as well as the financial burden on overall society in terms of the huge costs of nursing and patient care. Eisai remains deeply focused on the development of such therapies based on the knowledge and experience it has accumulated through its development of the anti-AD agent Aricept®. Through our collaboration with Biogen Idec, a company that specializes in neurodegenerative diseases, I believe we will be able to further enhance our existing R&D capacities for developing next-generation AD treatments, thereby accelerating the development of promising therapies and increasing the benefits provided to patients with AD worldwide.”

Advertisement